Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.71 |
| ▸ | YAP1 | P46937 | 1/20 | 0.68 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.68 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flufenamic Acid SCHEMBL1478282 | 1.00 | RXFP1 (0.71) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL9845498 | 0.97 | RXFP1 (0.71) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11788728 | 0.97 | RXFP1 (0.71) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11524550 | 0.97 | RXFP1 (0.71) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11794349 | 0.89 | RXFP1 (0.60) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11791445 | 0.88 | RXFP1 (0.57) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11791950 | 0.88 | RXFP1 (0.57) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11793234 | 0.88 | RXFP1 (0.57) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL17497 | 0.86 | RXFP1 (0.75) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL29356958 | 0.86 | RXFP1 (0.75) | RXFP1YAP1TEAD4TEAD2MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250332120-A1 | COMPOSITION FOR EXTERNAL PREPARATION | KAO CORPORATION (JP) | 2025-10-30 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4563161-A1 | COMPOSITION FOR EXTERNAL PREPARATION | Kao Corporation (JP) | 2025-06-04 | — | — | EP | disclosed |
| US-20230000917-A1 | TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION | UCL BUSINESS LTD (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-2887982-B1 | APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE BIOMEDICAL INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11504431-B2 | Formulations for the suprachoroidal space of an eye and methods | EMORY UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| EP-4065170-A1 | TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION | UCL Business Ltd (GB) | 2022-10-05 | — | — | EP | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022163694-A1 | COMPOSITION FOR EXTERNAL APPLICATION | 花王株式会社 | 2022-08-04 | — | — | WO | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022049414-A1 | NITAZOXANIDE FOR USE TO TREAT COVID-19 | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | RXFP1 4165/4885YAP1 1916/4885TEAD4 739/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | RXFP1 125/4885YAP1 803/4885TEAD4 1558/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | RXFP1 1340/4885YAP1 2287/4885TEAD4 224/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | RXFP1 4079/4885YAP1 1792/4885TEAD4 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.